Vlad Mazanko is Ukraine-based gaming enthusiast, writing about the industry since 2013 and covering everything from games and ...

"I want to play Final Fantasy on PS5, but there are so many titles that I don't know which one to buy." As someone who has been playing the FF series for many years, I will solve that problem for you.

It's been three years since Final Fantasy fans have been able to play as Clive Rosfield, the main protagonist of 2023's Final Fantasy XVI. Final Fantasy Resonance, a forthcoming turn-based ...

MILLBRAE, Calif., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to ...

Square Enix has today announced the epic action-RPG Final Fantasy XVI is coming to PC via Steam and Epic Games on September 17. To prepare players for the adventure that awaits, a free demo can be ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Eikon Therapeutics receives a Sell rating due to lock-up expiry risks despite a promising clinical strategy for EIK1001. EIKN's lead asset, EIK1001, shows encouraging early data in NSCLC and melanoma, ...

Creating excitement around Eikon is the fact that the biotech's founders are industry veterans who have worked on some of the world's most effective and best-selling cancer drugs - as per the ...

MILLBRAE, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to ...

Feb 5 (Reuters) - Drug developer Eikon Therapeutics , headed by Merck veteran Roger Perlmutter, was valued at about $860.3 million after its shares opened 5.3% below their offer price in their Nasdaq ...

Despite progress made in cancer immunotherapy, some patients don’t respond to these treatments or they stop responding after a period of time. Eikon Therapeutics’ lead drug candidate could address ...